Early Conversion to Aflibercept for Persistent Diabetic Macular Edema Results in Better Visual Outcomes and Lower Treatment Costs

References

• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–136. doi:10.1016/S0140-6736(09)62124-3
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 Phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039
   PubMed Web of Science ®Google Scholar
• Korobelnick JF, Do DV, Schmidt-Erfuth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254. doi:10.1016/j.ophtha.2014.05.006
   Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077 e35. doi:10.1016/j.ophtha.2010.02.031.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359. doi:10.1016/j.ophtha.2016.02.022
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022. doi:10.1016/j.ophtha.2013.02.034
   PubMed Web of Science ®Google Scholar
• Rahimy E, Shahlaee A, Khan MA, et al. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol. 2016;164:118–127.e2. doi:10.1016/j.ajo.2015.12.030
   PubMed Web of Science ®Google Scholar
• Ashraf M, Souka AA, ElKayal H. Short-term effects of early switching to ranibizumab or aflibercept in diabetic macular edema cases with non-response to bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017;48(3):230–236. doi:10.3928/23258160-20170301-06
   PubMed Web of Science ®Google Scholar
• Xiao K, Li FZ, Liang SZ, Wang J, Qian C, Wan GM. Efficacy of conversion to aflibercept for diabetic macular edema previously refractory to bevacizumab or ranibizumab: a meta-analysis of high-quality nonrandomized studies. Ann Pharmacother. 2020;54(8):750–756. doi:10.1177/1060028020904358
   PubMed Web of Science ®Google Scholar
• Giani A, Cigada M, Choudhry N, et al. Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol. 2010;150(6):815–824. doi:10.1016/j.ajo.2010.06.025
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, Landy J. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48(2):204–223. doi:10.1016/S0039-6257(02)00457-5
   PubMed Web of Science ®Google Scholar
• Ross EL, Hutton DW, Stein JD, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;134(8):888–896. doi:10.1001/jamaophthalmol.2016.1669
   PubMed Web of Science ®Google Scholar
• NHS. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. Section 5.6: discounting. London. NICE; 2013. Available from: https://www.nice.org.uk/process/pmg9/chapter/the-reference-case#discounting. Accessed August 19, 2020.
   Google Scholar
• Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology. 2013;120(9):1835–1842. doi:10.1016/j.ophtha.2013.02.002
   PubMed Web of Science ®Google Scholar
• Permsuwan U, Thavorn K, Dilokthornsakul P, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective. J Med Econ. 2017;20(9):991–999. doi:10.1080/13696998.2017.1347792
   PubMed Web of Science ®Google Scholar
• Li A, Rieveschl NB, Conti FF, et al. Long-term assessment of macular atrophy in patients with age-related macular degeneration receiving anti-vascular endothelial growth factor. Ophthalmol Retina. 2018;2(6):550–557. doi:10.1016/j.oret.2017.10.010
   Google Scholar
• Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2018;10:CD007419.
   PubMed Web of Science ®Google Scholar
• Ferris FL 3rd, Maguire MG, Glassman AR, Ying GS, Martin DF. Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema. JAMA Ophthalmol. 2017;135(2):145–149. doi:10.1001/jamaophthalmol.2016.4820
   Web of Science ®Google Scholar
• Holekamp N, Duff SB, Rajput Y, Garmo V. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data. J Med Econ. 2020;23(3):287–296. doi:10.1080/13696998.2019.1666855
   Web of Science ®Google Scholar
• Glassman AR, Wells JA 3rd, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). (published online ahead of print March 29, 2020). Ophthalmology. 2020;127(9):1201–1210. doi:10.1016/j.ophtha.2020.03.021.
   Web of Science ®Google Scholar
• Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS. RIDE and RISE Research Group. Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology. 2015;122(12):2504–2513.e1. doi:10.1016/j.ophtha.2015.08.006
   PubMed Web of Science ®Google Scholar
• Pieramici DJ, Wang PW, Ding B, Gune S. Visual and anatomic outcomes in patients with diabetic macular edema with limited initial anatomic response to ranibizumab in RIDE and RISE. Ophthalmology. 2016;123(6):1345–1350. doi:10.1016/j.ophtha.2016.02.007
   PubMed Web of Science ®Google Scholar
• Pieramici D, Singh RP, Gibson A, et al. Outcomes of diabetic macular edema eyes with limited early response in the VISTA and VIVID studies. Ophthalmol Retina. 2018;2(6):558–566. doi:10.1016/j.oret.2017.10.014
   Google Scholar
• Bressler SB, Ayala AR, Bressler NM, et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016;134(3):278–285. doi:10.1001/jamaophthalmol.2015.5346
   PubMed Web of Science ®Google Scholar
• Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100(11):1494–1498. doi:10.1136/bjophthalmol-2015-308264
   Web of Science ®Google Scholar
• Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc. 2009;107:311–324.
   PubMedGoogle Scholar